相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CLL update 2022: A continuing evolution in care
Neil E. Kay et al.
BLOOD REVIEWS (2022)
Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018
Lina van der Straten et al.
BLOOD CANCER JOURNAL (2022)
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
Andreas Agathangelidis et al.
BLOOD (2021)
Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
Peter Hillmen et al.
BLOOD (2021)
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study
Caspar da Cunha-Bang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
M. van Gelder et al.
ANNALS OF ONCOLOGY (2021)
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Lindsey E. Roeker et al.
BLOOD (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016
Lina van der Straten et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands
Lina van der Straten et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
Sonia Jaramillo et al.
HAEMATOLOGICA (2020)
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
Victor S. Lin et al.
BLOOD (2020)
Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies
Fernando Martin-Moro et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Anthony R. Mato et al.
CLINICAL CANCER RESEARCH (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M. Kuderer et al.
LANCET (2020)
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R. Mato et al.
BLOOD (2020)
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Lydia Scarfo et al.
LEUKEMIA (2020)
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
Lindsey E. Roeker et al.
BLOOD ADVANCES (2020)
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
Davide Rossi et al.
HEMASPHERE (2020)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Arnon P. Kater et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
Peter Dreger et al.
BLOOD (2018)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Max J. Gordon et al.
CANCER (2018)
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
Sabina Kersting et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
Andy C. Rawstron et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
J. Malcikova et al.
LEUKEMIA (2018)
A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies
Jan de Jong et al.
LEUKEMIA & LYMPHOMA (2018)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Paul M. Barr et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia
Lisa S. Chen et al.
BLOOD (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study
Anthony R. Mato et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
Qiushi Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations
R. Rosenquist et al.
LEUKEMIA (2017)
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
Iris de Weerdt et al.
HAEMATOLOGICA (2017)
FCR achieves long-term durable remissions in patients with IGHV-mutated CLL
Chatree Chai-Adisaksopha et al.
BLOOD (2017)
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients
Loic Ysebaert et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
A. R. Mato et al.
ANNALS OF ONCOLOGY (2017)
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Philip A. Thompson et al.
BLOOD (2016)
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
Kirsten Fischer et al.
BLOOD (2016)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
A. C. Rawstron et al.
LEUKEMIA (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Barbara Eichhorst et al.
LANCET ONCOLOGY (2016)
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
HAEMATOLOGICA (2016)
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Impact of Ibrutinib and Idelalisib on the Pharmaceutical Cost of Treating Chronic Lymphocytic Leukemia at the Individual and Societal Levels
Tait D. Shanafelt et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Ohad Benjamini et al.
LEUKEMIA & LYMPHOMA (2015)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia
Ilaria Del Giudice et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Infection outcomes in patients with common variable immunodeficiency disorders: Relationship to immunoglobulin therapy over 22 years
Mary Lucas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Trends in adult leukemia incidence and survival in Denmark, 1943-2003
Lau Caspar Thygesen et al.
CANCER CAUSES & CONTROL (2009)
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology
Graca A. M. Dores et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Diagnostic criteria for monoclonal B-cell lymphocytosis
GE Marti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
